Sarcoma and Solid Tumors

Solid tumors are masses that can grow almost anywhere in the body with the exception of the blog (hematological cancer). Solid tumors as split into two categories: sarcomas and carcinomas.

Our research team looks for ways to decrease the size and impact of solid tumors, or to slow the growth of the tumor in the safest way possible. This is determined through a combination of inhibitors, radiation treatments, and other therapies. Our researchers also evaluate tumors through biopsies to better understand what the genetic make-up of the tumor is and how it can be treated.

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

Protocol ID: ARST1321

Disease: Solid tumors

Who can participate?: Patients must be ≥ 2 years at the time of the biopsy that established the diagnosis of NRSTS will be eligible. BSA> 0.5m2

Lead Researcher: Mark A. Ranalli, MD

Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human Interferon beta in patients with refractory solid tumors

Protocol ID: Vyriad

Disease: Refractory Solid Tumors

Who can participate?: Patients must be > 365 days and < 31 years of age

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Subprotocol of Loxo-101 (Larotrectinib) in patients with tumors harboring actionable NTRK Fusions

Protocol ID: APEC1621A

Disease: Solid Tumors

Who can participate?: Patients must be greater than 12 months of age and less than 21 years of age at the time of study enrollment

Lead Researcher: Mark A. Ranalli, MD

MATCH-Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 Alterations

Protocol ID: APEC1621B

Disease: Solid tumors

Who can participate?: Be between 6 months and less than 18 years of age on day of signing informed consent/assent (NBL and Osteo closed)

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Sub protocol of Tazemetostat in Patients with Tumors Harboring Alterations in EXH2 or Members of the SWI/SNF complex

Protocol ID: APEC1621C

Disease: Solid tumors

Who can participate?: No specific age requirement

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Sub Protocol of Tazemetostat in patients with tumors harboring alternation in EZh2 or members of SWI/SNF complex

Protocol ID: APEC1621C

Disease: Solid tumor

Who can participate?: Patients must be ≤ 21 years of age at the time of diagnosis

Lead Researcher: Mark A. Ranalli, MD

MATCH Phase 2 Sub Protocol of LY3023414 in Patients with Solid Tumors

Protocol ID: APEC1621D

Disease: Solid Tumors

Who can participate?: Ages > 2 - < 19 years

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Sub protocol of Selumetinib (AZD6244 Hydrogen Sulfate) in patients with tumors harboring activating MAPK pathway mutations

Protocol ID: APEC1621E

Disease: Solid Tumor

Who can participate?: No specific age requirement

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Sub Protocol of Ensartinib patients with tumors harboring ALK or ROS1 genomic alterations

Protocol ID: APEC1621F

Disease: Solid tumors

Who can participate?: No specific age requirement

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Sub protocol of Vemurafenib in patients with tumors harboring BRAF V600 Mutations

Protocol ID: APEC1621G

Disease: Solid tumor

Who can participate?: Patients must be < 30 years of age

Lead Researcher: Mark A. Ranalli, MD

MATCH- APEC Screening Protocol for Molecular Analysis for Therapy Choice

Protocol ID: APEC1621SC

Disease: Solid tumor

Who can participate?: < 12 months of age at diagnosis with INRG Stage L1 or < 18 months of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma

Lead Researcher: Mark A. Ranalli, MD

A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens

Protocol ID: AOST06B1

Disease: OST

Who can participate?: There are no age limitations

Lead Researcher: Mark A. Ranalli, MD

Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Protocol ID: AOST1321

Disease: OST

Who can participate?: Patients must be equal to or greater than 11 years of age but less than 50 years of age at the time of enrollment

Lead Researcher: Mark A. Ranalli, MD

Renal Tumors Classification, Biology, and Banking Study

Protocol ID: AREN03B2

Disease: REN

Who can participate?: Patients must be < 30 years old at the time of diagnosis

Lead Researcher: Mark A. Ranalli, MD

A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol

Protocol ID: D9902

Disease: Soft tissue sarcoma

Who can participate?: Patients must be ≤ 50 years of age at time of enrollment

Lead Researcher: Mark A. Ranalli, MD

Investigation of Early Lymphocyte Recovery in Patients with Osteosarcoma

Protocol ID: Early Lymphocyte Recovery in Patients with Osteosarcoma

Disease: OST

Who can participate?: Patients ≥1 year and < 31 years of age at the time of relapse will be eligible

Lead Researcher: Nicholas D. Yeager, MD

A Phase I Dose Escalation Study of Intraturmoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients with Refractory Non-Central Nervous System (Non-CNS) Solid Tumors

Protocol ID: HSV-1716

Disease: Non-CNS Solid Tumor

Who can participate?: Subjects must be ≥7 years and ≤30 years of age at the time of being administered the first cycle of HSV1716 (Day 0)

Lead Researcher: Timothy Cripe, MD, PhD

NCH Solid Tumor Biology Study: Collection and Banking of Fresh Tumor and Serum Specimens for Research Purposes

Protocol ID: NCHB001

Disease: Solid tumors

Who can participate?: No specific age requirement

Lead Researcher: Bhuvana A. Setty, MD

A Phase II Study of Pazopanib (GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors

Protocol ID: ADVL1322

Disease: Solid tumors

Who can participate?: Patients must be at least 1 year and less than or equal to 18 years of age at the time of study entry.

Lead Researcher: Mark A. Ranalli, MD